Failure to thrive. Other lack of expected normal physiological development
Conditions
Interventions
Intervention 1: Cyproheptadine 0.25 mg/kg/day (twice daily) for 1 month. Intervention 2: Multivitamine, 0.25 mg/kg/d(twice daily) for 1 month.
Treatment - Drugs
Placebo
Cyproheptadine 0.25 mg/kg/day (twice daily) for 1 month
Multivitamine, 0.25 mg/kg/d(twice daily) for 1 month
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
2 Years to 5 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: children aged between2 to 5 years old and have mild to moderate failure to thrive. Exclusion criterion: Having organic causes or acute or chronic diseases.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: At begining of study, 1 month after begining and 1 month after termination of study. Method of measurement: Kilogram.;Height. Timepoint: At begining of study, 1 month after begining and 1 month after termination of study. Method of measurement: Cm. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drowsiness. Timepoint: During drug consumption. Method of measurement: History and Physical examination.;Restlessness. Timepoint: During drug consumption. Method of measurement: History and Physical Examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKhadijeh Sadat Najib
Shiraz University of Medical Sciences
Outcome results
None listed